Haisco Pharmaceutical (SHE:002653) said China's medical products regulator has accepted the investigational new drug application for HSK60002 tablets.
The drug was independently developed for treating inflammatory diseases, according to a Tuesday filing with the Shenzhen bourse.
Shares of the company fell 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.